Cullinan Therapeutics registers Phase 1b trial of CLN-049 with azacitidine, venetoclax in AML
New Phase 1b study will test CLN-049 combined with standard AML therapies in newly diagnosed patients who cannot tolerate intensive chemotherapy.
Cullinan Therapeutics registered one new trial this week.
- CLN-049, an investigational drug, entered a Phase 1b dose escalation and dose expansion study in combination with azacitidine and venetoclax for adults with newly diagnosed acute myeloid leukemia. The trial is not yet recruiting, with an estimated start of 2026-10-151, and plans to enroll 90 participants1. Eligible patients must be not candidates for intensive induction chemotherapy because they are either unfit or otherwise clinically unsuitable for anthracycline/cytarabine-based induction therapy1, and the study's primary outcome tracks incidence and severity of adverse events, adverse events of special interest, and serious adverse events of CLN-049 combined with azacitidine and venetoclax over a 48-week time frame1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.